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A Poliomyelitis-like Syndrome 
from West Nile Virus Infection
 
To the Editor: 
 
Muscle weakness is a common finding and





 Yet this important sign does not have a
defined pathological basis. In monkeys, horses, and birds,




 Our clinical and elec-
trodiagnostic findings in three consecutive patients with
confirmed West Nile virus infection suggest that the virus
also attacks the spinal cord in humans.
Patient 1, a 56-year-old man, presented with fever, chills,
night sweats, myalgias, and confusion. Weakness gradually
developed in his arms, along with flaccid paralysis in his right
leg, areflexia, bladder dysfunction, and acute respiratory dis-
tress. He reported that he had no pain or paresthesias. Sen-
sory examination was normal. Suspected diagnoses included
stroke, Guillain–Barré syndrome, and inflammatory myop-
athy, for which he received anticoagulation therapy and in-
travenous immune globulin and underwent muscle biopsy.
Cerebrospinal fluid showed 3 white cells per cubic millime-
ter, a glucose level of 54 mg per deciliter, and a protein level
of 89 mg per deciliter. Magnetic resonance imaging (MRI)
of the brain and cervical spine was normal. In an enzyme-
linked immunosorbent assay, the ratio of IgM antibodies
against West Nile virus (the ratio of the reactivity of the pa-
tient’s serum to West Nile virus antigen to the reactivity of
 



































































RIGHT LEFT RIGHT LEFT RIGHT LEFT
 
Median motor nerve (mV) Wrist Abductor pollicis 
brevis
3.9 — 3.8 — 2.0 11.4 »5.0
Median sensory nerve (µV) Wrist Second digit 20.4 — 34.4 — 33.4 35.4 »20.0
Ulnar motor nerve (mV) Wrist Abductor digiti 
minimi
5.0 — 4.4 — 1.6 7.5 »4.5
Ulnar sensory nerve (µV) Wrist Fifth digit 18.8 — 17.8 — 28.8 27.6 »15.0
Musculocutaneous motor
nerve (mV)
Erb’s point Biceps 2.4 — — — 0.2 7.6 »4.0
Musculocutaneous sensory
nerve (µV)
Elbow Forearm 10.6 — 17.2 — 27.1 32.6 »10.0
Axillary motor nerve (mV) Erb’s point Deltoid 1.7 — 0.3 — 0.4 5.3 »4.0
Radial sensory nerve (µV) Forearm Dorsum of hand 23.2 — 48.6 — 31.9 31.8 »15.0



















Peroneal sensory nerve (µV) Leg Dorsum of foot 2.2 3.1 6.6 7.1 — — »5.0
Tibial motor nerve (mV) Ankle Abductor hallucis 2.5 7.6 2.8 3.3 — — »3.0
Sural sensory nerve (µV) Posterior leg Ankle 8.4 9.7 13.3 14.8 — — »8.0
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control serum to the same antigen) was 14.78:1 (reference
ratio, <2.00:1). Electrodiagnostic studies showed reduced
motor responses, preserved sensory responses, and scattered
denervation without evidence of myopathy or polyneurop-
athy (Table 1).
Patient 2, a 57-year-old man, presented with fever, chills,
nausea, vomiting, and headache. Asymmetric flaccid paraly-
sis developed, involving the distal portion of the left leg, the
right thigh, and the right arm, as well as areflexia, dysphagia,
urinary incontinence, and acute respiratory distress requiring
mechanical ventilation. The patient reported having no al-
tered sensation. Sensory examination was normal except that
there was a slight decrease in vibratory sensation in the toes
bilaterally. Cerebrospinal fluid showed 80 white cells per
cubic millimeter, a glucose level of 99 mg per deciliter, and
a protein level of 196 mg per deciliter. The virus-specific
IgM ratio was 24.48:1. MRI of the brain was normal. Elec-
trodiagnostic studies showed reduced motor responses, nor-
mal sensory responses, widespread denervation, and neuro-
genic recruitment (Table 1).
Patient 3, a 50-year-old man, presented with severe nau-
sea, vomiting, headache, and diarrhea, but no fever. He was
given a diagnosis of food poisoning, but flaccid paralysis
developed, together with areflexia limited to the right arm,
without pain or paresthesias. Sensory examination was nor-
mal. He received anticoagulation therapy for suspected
stroke, although MRI of the brain was normal. The ratio
of IgM against West Nile virus was 2.08:1. No spinal tap
was performed. After the patient was transferred to a re-
habilitation hospital, the IgM ratio was 25.74:1. Electrodi-
agnostic studies showed markedly reduced motor respons-
es in the monoplegic limb, with normal sensory responses
(Table 1).
Asymmetric flaccid paralysis and areflexia developed in
all three patients, and two had bladder dysfunction and acute
respiratory distress. Electrodiagnostic findings confirmed in-
volvement of anterior horn cells or motor axons. These clin-
ical and electrodiagnostic findings are classic features of





 the spinal cord gray matter is a target of West
Nile virus. The poliomyelitis-like presentation in our cases
warrants a reevaluation of other cases of West Nile virus with
similar presentation that have previously been attributed




Awareness that muscle weakness with West Nile virus in-
fection may be of spinal origin should help to eliminate mis-
diagnoses and inappropriate treatment, and it should en-
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Poliomyelitis Due to West Nile Virus
 
To the Editor: 
 
Poliomyelitis is a clinical syndrome defined
by the presence of fever, meningitis, and flaccid paralysis. In
the United States, this syndrome was historically associated
with infection by poliovirus but is now more commonly seen
with other enteroviruses. We describe a case of poliomyelitis
in a patient infected with West Nile virus, a flavivirus.
A 50-year-old woman from Louisiana had a headache on
the day before she traveled to Georgia for the July 4 holiday.
After she arrived, her headache worsened, and she had severe
myalgia. Two days after the onset of headache, weakness de-
veloped, and the patient was admitted to the hospital. She
was febrile (temperature, 39.5°C) but was awake, alert, and
fully cognizant. She had moderate bifacial and appendicu-
lar weakness (Medical Research Council grade 4–5), with a
normal sensory examination and retained deep-tendon re-
flexes. Lumbar puncture showed 54 white cells per cubic
millimeter (22 percent neutrophils), with a normal glucose
level and a protein level of 110 mg per deciliter (normal lev-
el, <45 mg per deciliter).
She remained febrile through the eighth day. Her weak-
ness progressed, and she required intubation on the sixth
day after the onset of headache, when she could no longer
lift her head or move her arms or legs against gravity. Her
cognition, sensation, and reflexes remained normal. Magnet-
ic resonance images of the complete spinal cord were normal.
Serial electrodiagnostic findings are presented in Table 1.
On day 12 of hospitalization, a cerebrospinal fluid spec-
imen tested positive for antibodies against West Nile virus
(IgM titer, 1:256; IgG titer, 1:128). Stool cultures and poly-
merase-chain-reaction studies for the presence of enterovi-
ruses were negative. Two months after the onset of weakness,





































Sensory amplitudes Normal Normal Normal




Motor distal latencies Normal Normal Normal
Conduction velocities Normal Normal Normal
Spontaneous activity on 
electromyography
None None Profuse in proximal 
and distal muscles
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This unusual clinical presentation of paralytic poliomy-
elitis is distinguished from Guillain–Barré syndrome, the
most common cause of acute flaccid paralysis in the United
States, by the presence of fever, pleocytosis, and retained
tendon reflexes. Electrodiagnostic studies during the acute
phase of the illness confirmed the pure motor nature of her
illness, excluded demyelination as a pathogenic mechanism,
and identified the anterior horn cell as the site of pathology.
Previous reports of West Nile virus, including those from





 The mechanism underlying weakness in West
Nile virus has not been clearly established, and in some cases,
this symptom has been attributed to Guillain–Barré syn-
drome. Our data and those of previous studies are consis-
tent with effects at the level of the anterior horn cell. Autop-




Poliovirus attacks motor neurons by attaching to the po-
liovirus receptor on the anterior horn cell. Flaviviruses other
than West Nile virus are not known to cause poliomyelitis.
These findings raise the possibility that these viruses can
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Tissue Plasminogen Activator in Cardiac Arrest 
with Pulseless Electrical Activity
 
To the Editor: 
 










beneficial effects of fibrinolysis in patients with cardiac ar-
rest and pulseless electrical activity. However, Abu-Laban





 We are not aware of other studies in which there were
no survivors in the placebo group. Even therapeutic strate-





 would have failed in this study population.
To test validly for efficacy, it is important to study popu-
lations that might also survive without specific treatment.
Moreover, treatment with tissue plasminogen activator (t-PA)
was initiated a mean of 36 minutes after the patient’s col-
lapse, by which time ineffective resuscitation procedures
have mostly been terminated. Nevertheless, the group size
was calculated on the assumption that treatment would
change the rate of survival to hospital discharge from 1.0
percent (in the placebo group) to 10.3 percent (in the t-PA
group) — an increase of 930 percent. Such prerequisites
might a priori preclude the demonstration of any positive
effect of an intervention.




 the administration of
heparin was not mandatory. Nevertheless, 5 of 13 patients
(38 percent) who were admitted received heparin, which
may suggest an additional beneficial effect. Therefore, the
number of patients per group who received this medication
should be clarified.
For conclusive investigation of the effects of t-PA in car-
diac arrest, t-PA must be given early to patients with a better
prognosis, such as those with a witnessed arrest, ventricular
fibrillation, or both. Such a study is currently under way in
Europe, and when the results are available, the controversy
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hypothermia to improve outcome after cardiac arrest. N Engl J Med 2002;
346:549-56. [Erratum, N Engl J Med 2002;346:1756.]
 
To the Editor: 
 
Fibrinolytic, antiplatelet, and antithrombot-
ic agents are promising for the treatment of cardiac arrest.
Cardiopulmonary resuscitation (CPR) can alter the pharma-
cokinetics of these agents, making higher dosages or bolus
administration necessary. Laboratory studies must therefore
precede clinical trials. We have previously noted that the
grave nature of cardiac arrest may explain the tendency to
rush into clinical trials, but it may not justify the potential




Concern about the administration of a potentially harm-
ful agent under “implied consent” may not be mitigated by
using it late, when it may be ineffective. In this study, fibri-
nolysis may not have been achieved before irreversible injury
occurred.
Perfusion pressure during CPR is the difference between




 The administration of 500 ml
of intravenous saline is not standard practice and may de-
crease perfusion. Bicarbonate is additional volume, and li-





neither agent is part of standard therapy.
Because fewer patients who underwent autopsy had pul-
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 less than one quarter may have been suscepti-
ble to a benefit. The inclusion of patients with initial asys-
tole also reduced the proportion with a potential response.
This study population may not have been optimal, since oth-





 We refer to this as a “graveyard effect”; a
better term might be “rancid sample,” as proposed by the
late epidemiologist Dr. Alvan Feinstein. This study does not
“exclude” an increase in survival, because when the control
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To the Editor: 
 
We disagree with the suggestion that our
study was predestined to have negative results. Böttiger et al.
state that t-PA must be evaluated in patients with a witnessed
arrest, initial ventricular fibrillation, or both. Sixty-six per-
cent of our study population met this requirement. Paradis
et al. question research on subgroups with poor outcomes;
however, it has not been established that a high base-line sur-
vival rate is required to assess the management of pulseless
electrical activity validly. We specifically studied this rhythm





the documented potential for forward blood flow and good
outcomes despite prolonged pulselessness. Most reports on
fibrinolysis involve cases in which patients have pulseless
electrical activity and are expected to die, yet a review of 67
such cases showed a 75 percent survival rate and a mean du-




 Our sample-size requirement
was based on these reports and a more modest survival rate
of 30 percent for the targeted subgroup.
We anticipated that 1 percent of eligible patients would
survive; thus, the outcome in our placebo group was not
surprising. Of 467 ineligible patients with pulseless electri-
cal activity, 4.7 percent survived. Most such survivors have
an early response to the initial therapies that we thought
would have been inappropriate to omit before the admin-
istration of t-PA. Intravenous saline is considered standard
therapy for pulseless electrical activity by the British Colum-
bia Ambulance Service. The influence of fluids on perfusion
pressure, with the various causes of pulseless electrical activ-
ity, remains poorly understood. Neither bicarbonate nor li-
docaine was mandated by our protocol, and the proportions
of patients who received these agents reflect local practice.
We believe our time intervals represent the reality of out-
of-hospital administration of a reconstituted fibrinolytic
agent after a rapid trial of initial therapies. On the basis of
numerous reports, these intervals would not negate the pos-
sibility of a response. Unfortunately, the studies with pos-





 precluding a comparison with our trial. In re-
sponse to the question about heparin, of the five patients
who were given heparin, three received t-PA.
We agree that laboratory studies are helpful but certainly
do not believe we rushed into a clinical trial. Our study arose
logically from a foundation of numerous reports involving
humans, as did two recent articles calling for clinical trials




 In our article, we
candidly discuss the limitations of our study, many of which
the correspondents repeat, and note that our results do not
exclude the possibility of a role for fibrinolytic therapy. Al-
though we stand by our conclusions, we look forward to the
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Salmeterol for the Prevention of High-Altitude 
Pulmonary Edema
To the Editor: Sartori and colleagues (May 23 issue)1 dem-
onstrate the marked benefits of salmeterol in the secondary
prevention of high-altitude pulmonary edema. The authors
propose that this benefit occurs through changes in pulmo-
nary transepithelial sodium transport rather than hemody-
namic effects, because salmeterol did not alter the heart rate
or peak pulmonary pressures.
However, the authors did not assess the nasal transepi-
thelial potential difference at high altitude, nor did they
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determine the effect of salmeterol administration on this
gradient. Furthermore, there was no measurement of mean
pulmonary pressure, cardiac output, central filling pressures,
or systemic blood pressure. In addition, only a derived peak
systolic pulmonary pressure was determined, and this meas-
ure may not reflect changes in pulmonary vascular resistance.
We and others have demonstrated that inhaled albuterol
is associated with increases in cardiac output and decreases
in vascular stiffness without changing the heart rate or sys-
temic blood pressure.2,3 Moreover, these effects are associat-
ed with increased plasma albuterol concentrations and may
be attenuated by a nitric oxide synthase inhibitor.3 It has
previously been suggested that nitric oxide has a role in the
pathogenesis of high-altitude pulmonary edema. Concen-
trations of exhaled nitric oxide are reduced by hypoxia,4 and
inhaled nitric oxide is an effective therapy for high-altitude
pulmonary edema.5 Although we recognize the difficulties
involved in undertaking research at high altitude, we believe
that a more detailed assessment is needed before a signif-
icant hemodynamic effect of salmeterol in the prevention of
high-altitude pulmonary edema can be ruled out.
NICHOLAS L.M. CRUDEN, M.B., CH.B.
DAVID E. NEWBY, PH.D., D.M.
DAVID J. WEBB, M.D., D.SC.
University of Edinburgh Centre for Cardiovascular Science
Edinburgh EH3 9YW, United Kingdom
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2. Chowienczyk PJ, Kelly RP, MacCallum H, et al. Photoplethysmographic 
assessment of pulse wave reflection: blunted response to endothelium-
dependent beta2-adrenergic vasodilation in type II diabetes mellitus. J Am 
Coll Cardiol 1999;34:2007-14.
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To the Editor: Sartori et al. report that inhalation of high-
dose salmeterol (three times the normal dose) results in a 50
percent reduction in the incidence of high-altitude pulmo-
nary edema in susceptible persons who ascend rapidly to
high altitude. They attribute the beneficial effects to stim-
ulation of sodium reabsorption from the alveoli mediated
by b2-adrenergic receptors. Unfortunately, salmeterol is not
the right drug with which to test this hypothesis. Besides
stimulation of sodium reabsorption, salmeterol has several
other actions that might better explain the prevention of
high-altitude pulmonary edema. These actions include
tightening of the alveolar-capillary barrier and lowering
pulmonary-artery pressure directly and through mediation
by peripheral chemoreceptors, as well as indirectly through
hypoxic ventilatory stimulation1 and increased nitric oxide
production. The same authors have shown that Doppler ech-
ocardiography, in contrast to invasive measurements, reveals
a big overlap of systolic pulmonary-artery pressure between
susceptible persons with and without high-altitude pulmo-
nary edema.2 Thus, the absence of significantly higher pul-
monary-artery pressure with placebo does not rule out the
possibility that salmeterol was acting as a vasodilator, par-
ticularly during climbing, when pulmonary-artery pressures
were highest. A variable time between inhalation and the
measurement of pulmonary-artery pressure could be an-
other confounding factor. Finally, our recently published
observations3 of high red-cell counts and protein concentra-
tions without signs of inflammation in alveolar-lavage fluid
of persons with high-altitude pulmonary edema indicate that
the integrity of the alveolar-capillary barrier is disturbed in
early stages of the condition. Since intact epithelial-barrier
function is crucial for the reabsorption of alveolar fluid in
humans,4 our findings argue against stimulated fluid reab-
sorption as the mechanism of prevention of high-altitude
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To the Editor: Since the publication of a previous article
by Sartori et al.,1 we have been using albuterol (Ventolin) in-
halers or nebulizers in the Himalayas for the treatment of
patients with high-altitude pulmonary edema. Our anecdot-
al experience indicates an increase in the pulse-oximeter
reading after the administration of this drug in subjects
with high-altitude pulmonary edema. Clearly, a formal study
needs to be done. However, the studies by Sartori et al. raise
a question about persons who are susceptible to a life-threat-
ening illness such as high-altitude pulmonary edema: why
would they reexpose themselves to high altitudes, especially





1. Sartori C, Lipp E, Duplain H, et al. Prevention of high-altitude pulmo-
nary edema by beta-adrenergic stimulation of the alveolar transepithelial 
sodium transport. Am J Respir Crit Care Med 2000;161:A415. abstract.
To the Editor: The recent article on the use of salmeterol
for the prevention of high-altitude pulmonary edema omits
mention of the incidence of smoking among subjects in
the comparison groups. Cigarette smoke is an important
source of nitric oxide. Even though pulmonary-artery pres-
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sures measured by echocardiography at selected time points
showed no significant difference between the groups that
were compared, it is known that nitric oxide from cigarette
smoke can cause vasodilatation1,2 and has been shown to
affect amiloride-sensitive sodium channels directly.3,4 There-
fore, differential rates of cigarette smoking could introduce
a bias into such a study and affect the results.
PARTHAK PRODHAN, M.D.
NATAN N. NOVISKI, M.D.
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To the Editor: In his Perspective article,1 Voelkel propos-
es that inflammation is a causal factor in high-altitude pul-
monary edema. We suggest that recent evidence supports
a view that inflammation may not be pathogenetic in high-
altitude pulmonary edema. Rather, the condition has a hy-
drostatic basis with unique fluid characteristics. In catheter-
ization studies, Maggiorini et al.2 found that susceptible
subjects in whom high-altitude pulmonary edema develops
not only have very high pulmonary-artery pressures but are
also critically distinguished from those without high-alti-
tude pulmonary edema by microvascular pressures above
20 mm Hg. The stress-induced failure of alveolar capillaries
results in a generalized breach of the alveolar-capillary bar-
rier with leakage of erythrocytes and plasma constituents.
Bronchoalveolar-lavage studies performed in patients with
high-altitude pulmonary edema lasting more than a day2,3
have in some cases found high neutrophil counts and inflam-
matory cytokine concentrations, providing the strongest ev-
idence for the inflammatory theory of causality. In contrast,
Swenson et al.3 have very recently shown that there is no ev-
idence of inflammation of the alveolar space in climbers who
are susceptible to high-altitude pulmonary edema within
24 hours after their arrival at an altitude of 4559 m (there
may be mild alveolar hemorrhage and increased plasma pro-
tein levels but there are no increases in neutrophil counts
or cytokine concentrations); these findings applied to those
with high-altitude pulmonary edema and to those in whom
it developed within the next day. Similarly, there were no
elevations in the levels of a host of inflammatory cytokines
in circulating blood.4 Furthermore, harvested alveolar mac-
rophages from these subjects (both at low altitude and at
4559 m) do not release inflammatory or chemotactic cyto-
kines with alveolar hypoxia sufficient to cause high-altitude
pulmonary edema.5 These data suggest that inflammation
in high-altitude pulmonary edema is a secondary reaction
to the initial hydrostatic injury.
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The authors reply:
To the Editor: We found that subjects who are susceptible
to high-altitude pulmonary edema had a defect of the res-
piratory transepithelial sodium transport and that salmeter-
ol, at a dose known to stimulate this transport (and at the
upper limit of the dose recommended for the treatment of
asthma), decreased the incidence of pulmonary edema in
highly susceptible subjects. Drs. Bärtsch and Mairbäurl sug-
gest that alternative mechanisms, also discussed in our arti-
cle, were responsible for the favorable effects of salmeterol.
A few clarifications must be made, however. In studies using
vasodilator agents to treat or prevent high-altitude pulmo-
nary edema, the decreases in systolic pulmonary-artery pres-
sure needed to attain this aim were large and were easily
detectable by echocardiography.1,2 The integrity of the alve-
olar-capillary barrier is not an absolute condition for the
stimulatory effects of b-adrenergic agonists on sodium
transport in the lung,3 and the evidence of a disruption of
this barrier during the development of high-altitude pulmo-
nary edema is scanty at best. Moreover, salmeterol tightens
the alveolar-capillary barrier, which may explain why its stim-
ulatory effect on sodium and water transport is preserved
even in the presence of a hypothetical disturbance of the
function of the alveolar capillary barrier.
Dr. Cruden and colleagues ask for invasive hemodynamic
measurements at high altitude and refer to work using sur-
rogate measurements of cardiac output and systemic arte-
rial stiffness after inhalation of albuterol. Although the rel-
evance of such observations with regard to pulmonary
vascular responses to salmeterol at high altitude is not ob-
vious, invasive hemodynamic measurements in subjects sus-
ceptible to high-altitude pulmonary edema would certainly
be of interest. However, we have some serious concern about
whether, for this specific issue, the potential gain in knowl-
edge justifies the risks related to the use of invasive meas-
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urements in seriously ill subjects in a high-altitude setting.
Dr. Prodhan and colleagues refer to smoking-related in-
halation of nitric oxide, an effective treatment for high-
altitude pulmonary edema,1 as a potential confounding var-
iable. None of the subjects smoked.
Dr. Basnyat’s observation of a benefit of albuterol inha-
lation for the treatment of established high-altitude pul-
monary edema is very interesting and concurs with similar
anecdotal experiences of others. It clearly deserves formal
testing. We also agree with his caveat regarding the risks of
reexposure to high altitude in subjects susceptible to high-
altitude pulmonary edema.
The dispute over the exact underlying mechanism by
which salmeterol may cause its favorable effects should not
obscure the primary new conclusion of the study for prac-










1. Scherrer U, Vollenweider L, Delabays A, et al. Inhaled nitric oxide for 
high-altitude pulmonary edema. N Engl J Med 1996;334:624-9.
2. Hackett PH, Roach RC. High-altitude illness. N Engl J Med 2001;345:
107-14.
3. Sartori C, Matthay MA, Scherrer U. Transepithelial sodium and water 
transport in the lung: major player and novel therapeutic agent in pulmo-
nary edema. Adv Exp Med Biol 2001;502:315-38.
Sirolimus-Eluting Coronary Stents
To the Editor: The results of the RAVEL study (Random-
ized Study with the Sirolimus-Coated Bx Velocity Balloon-
Expandable Stent in the Treatment of Patients with de Novo
Native Coronary Artery Lesions) (June 6 issue)1 are prom-
ising and bring to light the ethical and financial dilemma
that is likely to surface once drug-eluting stents are approved
for general use. The projected cost of each stent is likely to
be about $3,200. Of course, from a financial and societal
standpoint, it will not be possible to deploy drug-eluting
stents in every case of percutaneous coronary-stent interven-
tion. From an individual patient’s standpoint, a drug-elut-
ing stent may be a panacea for a given treated lesion. How
does one arrive at a balance? In what cases should the use
of a drug-eluting stent be considered absolutely justified
and maybe even crucial? We need to arrive at guidelines to
determine the point at which the cost of the device offsets
the need for repeated coronary interventions, especially in
situations in which the risk of restenosis is high or in which
presentation with restenosis will probably result in coronary-
artery bypass surgery. For example, in patients with diabetes
who have a long diseased segment in a small-caliber, proxi-
mal left anterior descending artery, treatment with a drug-
eluting stent may make good sense. However, a focal lesion
in a large-caliber, distal right posterolateral branch in a non-








1. Morice M-C, Serruys PW, Sousa JE, et al. A randomized comparison 
of a sirolimus-eluting stent with a standard stent for coronary revascular-
ization. N Engl J Med 2002;346:1773-80.
Dr. Morice replies:
To the Editor: Sharma and colleagues raise a crucial issue.
The cost of drug-eluting stents is indeed very high. Howev-
er, this high initial cost is expected to be significantly offset
by the reduced rate of recurrent events and the subsequent
reduced need for repeated intervention observed in our
study at one year among the recipients of sirolimus-eluting
stents. The cost-effectiveness analysis that was an objective
of the RAVEL trial should provide a clearer picture of the
financial aspects of the use of these new devices. As they
are increasingly used, the price of these stents is likely to
decrease, as is often the case with any new device.
In the meantime, the frustration felt by physicians and
their patients in view of the financial dilemma rightfully un-
derlined by Sharma et al. seems more than justified. Never-
theless, the spectacular therapeutic progress brought about
by the drug-eluting stents is a reality that cannot be denied.
The following RAVEL investigators were inadvertently
omitted in the Appendix to our article: C.R. Costantini,
M. de Freitas Santos, S.G. Tarbine, D.A. Zanerttini, and
J.L. Lazarte, Clínica Cardiológyca C. Costantini, Curitiba
Paraná, Brazil.
MARIE-CLAUDE MORICE, M.D.
Institut Cardiovasculaire Paris Sud
91300 Massy, France
mc.morice@icps.com.fr
Institutional Review Board Reform
To the Editor: A “central institutional review board,” as
proposed by Christian et al. (May 2 issue),1 may be a nation-
al ethics review board or a central research ethics commit-
tee, but it cannot be an institutional review board (IRB).
By definition, a central board “at the national level” tran-
scends an institution.
The continued use of the term “institutional review
board” may merely be the result of a habit that is hard to
break, or it might reflect something deeper. The term does
not contain the word “ethics,” implicitly elevating the in-
stitutional focus over the ethical focus. It also suggests that
local IRBs should still have ultimate authority, despite the
problems of duplicative reviews, dissipation of resources,
delays, lack of experience and expertise, and conflicts of in-
terest that are inherent in institution-based reviews. We
should not continue to use inaccurate labels that also send
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the wrong message and impede acceptance of a more cen-
tralized review process.
EZEKIEL J. EMANUEL, M.D., PH.D.
National Institutes of Health
Bethesda, MD 20892-1156
1. Christian MC, Goldberg JL, Killen J, et al. A central institutional review 
board for multi-institutional trials. N Engl J Med 2002;346:1405-8.
To the Editor: The articles by Steinbrook,1 Christian et al.,2
and Slater3 (May 2 issue) addressed IRB reform as a means
of improving the protection of research subjects. On the
basis of my experience as chairman of the IRBs at two major
academic medical institutions for a total of 18 years, I would
argue that serious risk to patients is more likely to be the
result of human fallibility than of inadequate IRB proce-
dures. Adequate IRB procedures could not have prevented
the deaths of the student at the University of Rochester
from an excessive dose of lidocaine, the volunteer at Johns
Hopkins from the pulmonary damage inflicted by hexameth-
onium, the patient at the University of Pennsylvania from a
genetically modified agent, or the nurse at Case Western
Reserve from an overdose of methionine. These deaths were
the result of a variety of human failings. The most zealous
overhaul of IRB regulations and the expenditure of substan-
tial sums to enforce them cannot avert the harm that results
from unexpected events or is inflicted by an investigator’s
sociopathy, hubris, or carelessness.
However, I do believe that an increased emphasis on whis-
tle-blower mechanisms can deal more effectively with the
potential problems engendered by the character flaws of in-
vestigators. Members of the research community, at all lev-
els, should be made aware of their responsibility to report
deviations from protocol. Such mechanisms exist to deal
with misconduct in science. They should be vigorously ap-
plied in medical research.
DONALD S. KORNFELD, M.D.
Columbia University College of Physicians and Surgeons
New York, NY 10032
dsk3@columbia.edu
1. Steinbrook R. Improving protection for research subjects. N Engl J 
Med 2002;346:1425-30. [Erratum, N Engl J Med 2002;346:1838.]
2. Christian MC, Goldberg JL, Killen J, et al. A central institutional re-
view board for multi-institutional trials. N Engl J Med 2002;346:1405-8.
3. Slater EE. IRB reform. N Engl J Med 2002;346:1402-4.
To the Editor: Christian and colleagues have provided an
informative explication of the operations of a central insti-
tutional review board (CIRB) associated with the National
Cancer Institute. The authors’ statement that the “diverse
perspectives and expertise of the board’s members have re-
sulted in a rich discussion of issues that is unmatched by
many local IRBs” must be supported. I suggest that the
board make public its deliberations. This action will permit
the members of other IRBs, potential trial participants, and
the general public to judge the manner in which the CIRB
members evaluate whether the requirements for the ethical
conduct of clinical research are met. Other IRBs may sub-
sequently decide to adopt those features of the CIRB’s re-
view process that they deem meritorious or to acquire mem-
bers with an equivalent range of expertise.
Making this material publicly accessible will also set an
important precedent with respect to ending the traditional,
but unjustified, secrecy surrounding the deliberations of
IRBs.1 It will do so notwithstanding the fact that the min-
utes of the CIRB will be subject to public disclosure pur-
suant to an applicable law in the State of Maryland taking
effect on October 1, 2002.2
HOWARD MANN, M.D.
University of Utah School of Medicine
Salt Lake City, UT 84132
howard.mann@hsc.utah.edu
1. Ashcroft R, Pfeffer N. Ethics behind closed doors: do research ethics 
committees need secrecy? BMJ 2001;322:1294-6.
2. Human Subject Research — Institutional Review Boards, House Bill 
917, Md. (2002).
To the Editor: The recent efforts detailed by Dr. Stein-
brook toward “improving protection for research subjects”
should not cause us to forget how the current system treats
subjects who are, in fact, injured by virtue of their partic-
ipation in research. Specifically, we must ensure that persons
who suffer research-related injuries do not have to bear the
additional indignity of having to pay for such injuries out
of their own pockets. Unfortunately, they largely have to do
so under the current system. This is ethically indefensible.
We all benefit from medical research. People who become
research subjects are exposed to the small but real chance
of being injured; we should all pay for these injuries. The
President’s Commission for the Study of Ethical Problems
in Medicine and Biomedical and Behavioral Research pub-
lished a report in 1982 calling for a national policy for the
compensation of subjects for research-related injuries.1 This
theme was echoed by the Advisory Committee on Human
Radiation Experiments.2 Despite these efforts, no national
policy to protect human subjects from being stuck with a
bill for expenses due to research-related injuries has been
established. A number of other countries have such policies
in place. It is time that the United States followed suit.
MICHAEL K. PAASCHE-ORLOW, M.D., M.P.H.




1. President’s Commission for the Study of Ethical Problems in Medicine 
and Biomedical and Behavioral Research. Compensating for research inju-
ries: the ethical and legal implications of programs to redress injured sub-
jects. Vol. 1. Washington, D.C.: Government Printing Office, 1982.
2. Advisory Committee on Human Radiation Experiments. ACHRE re-
port. Washington, D.C.: Department of Energy, 2002. (Accessed September 
26, 2002, at http://tis.eh.doe.gov/ohre/roadmap/achre/.)
Pleural Effusion
To the Editor: The criteria discussed by Light in his Clin-
ical Practice article on pleural effusion (June 20 issue)1 are
stringent and highly sensitive in identifying an exudate.
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However, their specificity is low, particularly in patients
with heart failure. Studies have shown that up to one third
of pleural-fluid specimens from the subgroup of patients
with the sole diagnosis of congestive heart failure fulfill at
least one of Light’s criteria for an exudate.2,3 We found that
patients with congestive heart failure who had false positive
results were more likely to meet only one of Light’s criteria
and to have received intravenous diuretics within 24 hours
before the pleural tap. A possible explanation is that diuret-
ics shift fluids from the pleural space, thereby changing bio-
chemical transudates into exudates.4
A careful evaluation of the number of positive criteria and
of whether a patient has recently received diuretic treatment
could improve the specificity of Light’s criteria in patients
with congestive heart failure. 





1. Light RW. Pleural effusion. N Engl J Med 2002;346:1971-7.
2. Gotsman I, Fridlender Z, Meirovitz A, Dratva D, Muszkat M. The eval-
uation of pleural effusions in patients with heart failure. Am J Med 2001;
111:375-8.
3. Vives M, Porcel JM, Vincente de Vera MC, Ribelles E, Rubio M. A 
study of Light’s criteria and possible modifications for distinguishing exu-
dative from transudative pleural effusions. Chest 1996;109:1503-7.
4. Chakko SC, Caldwell SH, Sforza PP. Treatment of congestive heart fail-
ure: its effect on pleural fluid chemistry. Chest 1989;95:798-802.
Dr. Light replies:
To the Editor: I agree with Drs. Fridlender and Gotsman
that pleural-fluid samples from many patients with conges-
tive heart failure fulfill at least one of Light’s criteria for an
exudate. I would add that laboratory values for patients with
heart failure alone that fulfill Light’s criteria for an exudate
usually only barely do so. As I mentioned in the article,
measuring the difference between the serum and the pleu-
ral-fluid albumin levels is useful in such patients since a dif-
ference greater than 1.2 g per deciliter is consistent with a
transudative effusion, even though other criteria for an ex-
udative effusion have been met.1




1. Burgess LJ, Maritz FJ, Taljaard JJ. Comparative analysis of the biochem-
ical parameters used to distinguish between pleural transudates and exudates. 
Chest 1995;107:1604-9.
Cryptosporidiosis
To the Editor: We wish to elaborate on the risks and pre-
vention of nosocomial cryptosporidiosis, briefly discussed
in the review of cryptosporidiosis by Chen and colleagues
(May 30 issue).1 Multiple nosocomial outbreaks of cryp-
tosporidiosis have resulted from direct and indirect person-
to-person transmission; one outbreak was due to spread of
the parasite from an ice chest contaminated by a patient.2
Cryptosporidiosis in adults should be managed with the use
of standard precautions; in incontinent or diapered children
less than six years of age, it should be managed with contact
precautions. This recommendation of the Centers for Dis-
ease Control and Prevention was recently validated in a ret-
rospective cohort study of 37 hospitalized patients that failed
to identify roommate-to-roommate transmission of
cryptosporidia.3
Cryptosporidium parvum has been shown to be resistant
to the germicides used for disinfection, including quaternary
ammonium compounds, phenolic compounds, 70 percent
ethyl alcohol, and 2.4 percent glutaraldehyde.4 The absence
of outbreaks due to use of gastrointestinal endoscopes prob-
ably results from physical removal of the organisms by clean-
ing and rapid inactivation of C. parvum by drying.4 Proper
cleaning before disinfection is therefore crucial to the pre-
vention of cross-transmission by gastrointestinal endoscopes,
since cleaning removes approximately 10,000 organisms.
C. parvum is relatively resistant to chlorine at the levels
used in potable water. For this reason, it has been recom-
mended that patients who are infected with the human
immunodeficiency virus5 and those who have received he-
matopoietic stem-cell transplants6 minimize their risk of
acquiring cryptosporidiosis from water by drinking either
filtered water or water that has been boiled for at least one
minute. It may be prudent for hospitals to provide all immu-
nocompromised persons with sterile water and sterile ice.
DAVID J. WEBER, M.D., M.P.H.
University of North Carolina at Chapel Hill
Chapel Hill, NC 27599-7030
dweber@unch.unc.edu
WILLIAM A. RUTALA, M.P.H., PH.D.
University of North Carolina School of Public Health
Chapel Hill, NC 27599
1. Chen X-M, Keithly JS, Paya CV, LaRusso NF. Cryptosporidiosis. 
N Engl J Med 2002;346:1723-31.
2. Weber DJ, Rutala WA. The emerging nosocomial pathogens Cryptospo-
ridium, Escherichia coli O157:H7, Helicobacter pylori, and hepatitis C: epi-
demiology, environmental survival, efficacy of disinfection, and control 
measures. Infect Control Hosp Epidemiol 2001;22:306-15.
3. Bruce BB, Blass MA, Blumberg HM, Lennox JL, del Rio C, Hors-
burgh CR Jr. Risk of Cryptosporidium parvum transmission between hos-
pital roommates. Clin Infect Dis 2000;31:947-50.
4. Barbee SL, Weber DJ, Sobsey MC, Rutala WA. Inactivation of 
Cryptosporidium parvum oocyst infectivity by disinfection and sterilization 
processes. Gastrointest Endosc 1999;49:605-11.
5. 1999 USPHS/IDSA guidelines for the prevention of opportunistic in-
fections in persons infected with human immunodeficiency virus. MMWR 
Morb Mortal Wkly Rep 1999;48(RR-10):1-59, 61-6.
6. Guidelines for preventing opportunistic infections among hematopoie-
tic stem cell transplant recipients: recommendations of the CDC, the In-
fectious Diseases Society of America, and the American Society of Blood 
and Marrow Transplantation. MMWR Morb Mortal Wkly Rep 2000;
49(RR-10):1-125.
Weight Loss in HIV-Infected Patients 
To the Editor: Recent reports have highlighted the risk
of hyperlactatemia and multiorgan failure in human im-
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munodeficiency virus (HIV)–infected patients receiving
interferon plus ribavirin for chronic hepatitis C.1,2 The mi-
tochondrial toxicity of nucleoside analogues seems to be as-
sociated with these effects. Hyperlactatemia and pancreatitis
have also recently been reported in patients taking didano-
sine and ribavirin.2,3 Since in vitro studies have shown that
the presence of ribavirin reduces the amount of didanosine
needed to suppress HIV,3 it is not surprising that potenti-
ation of didanosine by ribavirin may increase its toxicity.
Available data seem to confirm that there is a greater risk
of pancreatitis when stavudine or didanosine is taken con-
currently with therapy for hepatitis C virus (HCV) infection
than when other nucleoside analogues are used.4
We wondered whether other side effects of nucleoside an-
alogues might also be potentiated by ribavirin. During the
course of a trial of interferon plus ribavirin, we noticed a
rapid and significant loss of body weight among the HIV-
infected subjects initially recruited for the study (up to 9 kg
within six months in one patient). Likewise, the patients
described by Lafeuillade et al.1 and others2 presented with
asthenia, remarkable weight loss, and hyperlactatemia.
To assess whether synergistic toxicity between ribavirin
and nucleoside analogues was responsible for the significant
weight loss we observed, we analyzed 47 patients coinfected
with HIV and HCV (83 percent male; mean age, 38 years)
who completed six months of therapy with interferon (3 mil-
lion U three times per week) plus ribavirin (400 mg twice
daily) while receiving antiretroviral therapy. At base line,
their mean CD4 count was 573 per cubic millimeter, and 60
percent had plasma HIV RNA levels below 50 copies per
milliliter. Significant weight loss occurred during therapy for
HCV (approximately 4 kg, on average) in parallel with el-
evations in the serum lactate and amylase levels (Table 1). A
trend toward an association between higher lactate and
amylase levels and more pronounced weight loss was found
among patients taking didanosine or stavudine, as compared
with those taking other nucleoside analogues. We have not,
in our experience, observed comparable weight loss in pa-
tients taking interferon plus ribavirin alone or in those tak-
ing antiretroviral drugs.
Our observations support the existence of synergistic
toxicity, probably mitochondrial, between nucleoside ana-
logues and interferon plus ribavirin. Our findings mandate
the monitoring of lactate, amylase, and body weight in pa-
tients coinfected with HIV and HCV who are receiving an-
tiretroviral and anti-HCV therapy, so as to allow early rec-
ognition of serious toxic effects. Substantial weight loss
should be appreciated as a frequent and characteristic side




VINCENT SORIANO, M.D., PH.D.
Instituto de Salud Carlos III
28029 Madrid, Spain
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*Plus–minus values are means ±SD.
†P values are for the comparison with base-line values.
TABLE 1. WEIGHT AND BIOCHEMICAL VARIABLES 
DURING TREATMENT WITH INTERFERON PLUS RIBAVIRIN 
IN 47 PATIENTS COINFECTED WITH HCV AND HIV 










Body weight (kg) 70±11 66.3±11 0.01 66.1±11 <0.001
Lactate (mmol/liter) 1.9±0.4 2.2±0.5 0.04 2.25±0.33 0.047
Amylase (U/liter) 78±25 94±35 <0.001 128±187 <0.001
Aspartate aminotrans-
ferase (U/liter)
92±59 47±34 <0.001 62±84 <0.001
Alanine aminotrans-
ferase (U/liter)
133±83 56±49 <0.001 75±120 <0.001
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